Glaxosmithkline is seeking to sell its portfolio of consumer products worth £1.5-2 billion, The Wall Street Journal reports. The potential bidders for the deal include Advent International, Warburg Pincus and Cinven.

The over-the-counter products, which are primarily sold in Europe and the U.S., created revenues of nearly £500 million in 2010. Goldman Sachs is organizing the auction of the portfolio.

Click here for the story from The Wall Street Journal.

Click here for additional coverage from Reuters.